After Month of Bad News, Applied Shuffles Leadership, Lays Out Uncertain Path for Rare Disease Drug

Following a 90% drop in share price due to an FDA rejection and a warning letter over Applied Therapeutics’ conduct during a clinical trial, the biotech’s CEO has stepped aside.